Danaher CEO to Comment on Financial Performance

Rhea-AI Summary

Danaher (NYSE: DHR) has announced that CEO Rainer M. Blair will discuss the company's Q4 2024 performance at the J.P. Morgan Healthcare Conference. The company expects Q4 2024 revenues to show a low-single digit percent increase year-over-year. The estimated non-GAAP core revenue for Q4 2024 is projected to be flat year-over-year, surpassing previous guidance which had anticipated a low-single digit percent decline. The company will hold its Q4 and full year 2024 earnings conference call on January 29, 2025.

Positive

• Q4 2024 revenues expected to increase in low-single digit percent range
• Non-GAAP core revenue performance better than previous guidance
• Core revenue expected flat vs. previously guided decline

Negative

• None.

Insights

Financial Analyst

The preliminary Q4 revenue guidance from Danaher presents a noteworthy deviation from previous expectations. The projection of flat core revenue versus the earlier anticipated decline suggests improved operational execution and market dynamics. For a $169.8B market cap company, this outperformance relative to guidance is particularly meaningful.

Breaking down the metrics: The expected low-single digit percent increase in reported revenues, combined with flat core revenue, indicates that acquisitions or currency effects are contributing positively to the top line. This resilience in core revenue, especially given the challenging macro environment and healthcare spending patterns, demonstrates Danaher's robust business model and market positioning.

The timing of this announcement at the J.P. Morgan Healthcare Conference is strategic, as it's typically a catalyst-rich event where companies set their tone for the year. The positive revision to previous guidance could help shift market sentiment ahead of the full earnings release on January 29th.

Market Research Analyst

The healthcare sector's dynamics make this guidance particularly relevant. The flat core revenue performance, beating previous expectations of a decline, suggests potential stabilization in key markets such as diagnostics and life sciences. This could signal broader sector resilience, especially important given recent concerns about healthcare spending patterns.

Contextually, Danaher's performance often serves as a bellwether for the broader life sciences and diagnostics market. The improved outlook might indicate a faster-than-expected normalization of post-pandemic demand patterns, particularly in diagnostic testing and life sciences research segments. This has implications for both the company's competitive positioning and the broader industry trajectory.

WASHINGTON, Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT.

• For the fourth quarter 2024, estimated revenues are anticipated to increase in the low-single digit percent range year-over-year.
• Estimated non-GAAP core revenue for the fourth quarter of 2024 is expected to be essentially flat year-over-year, which would be above the Company's previously announced guidance of a low-single digit percent decline.

As previously announced, Danaher will hold its quarterly earnings conference call for the fourth quarter and full year 2024 on Wednesday, January 29, 2025 at 8:00 a.m. ET.

ABOUT DANAHER

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.  Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world.  Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies.  Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow.  Explore more at www.danaher.com.

NON-GAAP MEASURE AND SUPPLEMENTAL MATERIAL

This release contains the non-GAAP financial measure of core revenue.  A calculation of this measure, an explanation of what the measure represents and the reasons why we believe this measure provides useful information to investors, a reconciliation of the measure to the most directly comparable GAAP measure and other information relating to the non-GAAP measure are included in the supplemental reconciliation schedule attached.

In addition, this earnings release (including the supplemental reconciliation schedule) and a note containing details of Danaher's estimated financial performance have been posted to the "Investors" section of Danaher's website (www.danaher.com).

FORWARD-LOOKING STATEMENTS

Statements in this release that are not strictly historical, including the statements regarding the estimated financial results for the fourth quarter of 2024 and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.  These factors include, among other things: unanticipated, further declines in demand for our COVID-19 related products, the impact of global health crises, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations and fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2023 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2024.  These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

Estimated Sales Growth and Core Sales Growth

	% Estimated Change Three-Month Period Ended December 31, 2024 vs. Comparable 2023 Period
Total sales growth (GAAP)	+Low-single digit
Impact of:
Acquisitions/divestitures	-Low-single digit
Currency exchange rates	+Essentially flat
Core sales growth (non-GAAP)	+Essentially flat

 

Statement Regarding Non-GAAP Measures

Core sales growth should be considered in addition to, and not as a replacement for or superior to, sales growth, and may not be comparable to similarly titled measures reported by other companies. Management believes that this measure provides useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to sales growth, help our investors identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers.

Management uses core sales growth to measure the Company's operating and financial performance, and uses core sales growth as one of  the performance measures in the Company's executive short-term cash incentive program.

With respect to this non-GAAP measure, we exclude (1) the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, and (2) the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary dramatically from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult.

View original content:https://www.prnewswire.com/news-releases/danaher-ceo-to-comment-on-financial-performance-302349689.html

SOURCE Danaher Corporation

FAQ

What is Danaher's (DHR) expected revenue growth for Q4 2024?

Danaher expects Q4 2024 revenues to increase in the low-single digit percent range year-over-year.

How does DHR's Q4 2024 core revenue forecast compare to previous guidance?

DHR's Q4 2024 core revenue is expected to be flat year-over-year, performing better than the previously guided low-single digit percent decline.

When will Danaher (DHR) report its Q4 2024 earnings?

Danaher will hold its Q4 and full year 2024 earnings conference call on January 29, 2025, at 8:00 a.m. ET.

Where will Danaher's CEO present the Q4 2024 performance update?

Danaher's CEO will present at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT on January 14, 2025.